Cabiralizumab (FPA 008) is an anti-CSF1Rmonoclonal antibody (MAb). Cabiralizumab enhances T cell infiltration and antitumor T cell immune responses. Cabiralizumab inhibits the activation of osteoclasts and blocks bone destruction, and can be used in the research of rheumatoid arthritis (RA). Cabiralizumab can combine withNivolumab(HY-P9903) for lungcancerresearch^[1][2].

CSF1R^[1]

1613144-80-1

Please store the product under the recommended conditions in the Certificate of Analysis.